🇺🇸 FDA
Pipeline program

TAK-385

C27003 Merge to Takeda

Phase 2 small_molecule completed

Quick answer

TAK-385 for Prostate Cancer is a Phase 2 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Prostate Cancer
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials